BIRMINGHAM, Ala., Nov. 20 /PRNewswire-USNewswire/ -- Southern Research Institute today announced that Andrew D. Penman, Ph.D., has been named vice president of its Drug Development Division. Dr. Penman will lead Southern Research's preclinical contract research operations in toxicology, bioanalytical sciences, infectious diseases, cancer therapeutics and immunology.
(Photo: http://www.newscom.com/cgi-bin/prnh/20081120/DC47713)
"We are very pleased that Dr. Penman has joined Southern Research," said John A. "Jack" Secrist, III, Ph.D., president and CEO of Southern Research. "His international expertise and management experience in the CRO industry will be pivotal in our expansion and growth efforts domestically, and as we position our R&D services abroad in the biotech and pharmaceutical industry."
Before joining Southern Research, Penman served as vice president of Preclinical Development for Angiotech Inc. in Canada where he directed the company's global preclinical research and development activities focusing on pain, inflammation and wound closure areas. He also led the company's Vascular Wrap(TM) project team with submissions in the EU and U.S. Prior to that, Penman was president of preclinical technologies at Aptuit. He also held scientific management positions at Pharmacia in the US, Cephac Europe SA in France, and Quintiles Scotland.
"I look forward to helping Southern Research execute its strategies to capitalize on the increasing market opportunities for preclinical drug and vaccine research and clinical trial support services, both in the U.S. and internationally. This is a unique opportunity, and I am honored to join the Southern Research team," said Penman.
Penman earned his Bachelor's degree in chemistry from Heriot-Watt University in Edinburgh, Scotland and his Doctorate degree from the University of Kent in the United Kingdom.
About Southern Research
Southern Research Institute is a nonprofit 501(c) 3 scientific research organization that conducts basic research in drug discovery for cancer, emerging infectious diseases, and diseases of the central nervous system; contract research in drug and vaccine preclinical development; and, advanced engineering research in materials, systems development, environment and energy. Our more than 600 scientific and engineering team members support clients and partners in the pharmaceutical, biotechnology, defense, aerospace, environmental and energy industries. Southern Research is headquartered in Birmingham, Ala., with facilities also located in Wilsonville, Ala., Anniston, Ala., Frederick, Md., Durham, NC, and Fort Leonard Wood, Mo. For more information about Southern Research and its capabilities and accomplishments, visit www.SouthernResearch.org.
CONTACT: Rhonda Jung of Southern Research, +1-205-581-2317,
jung@southernresearch.org; or Risa Burgess or Nick Gosselin,
+1-781-684-0770, southern@schwartz-pr.com, for Southern Research Institute
Web site: http://www.southernresearch.org/